In vitro and in vivo studies with thymosin in cancer patients

L. A. Schafer, A. L. Goldstein, J. U. Gutterman, Evan M Hersh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Thymosin, fraction V, prepared by the method of Goldstein et al., was studied in in vitro lymphocyte cultures with cells obtained from normal subjects and patients with disseminated cancer. Thymosin lowered blastogenic activity in some patients, did not affect it in others, and increased counts in still others. There was a statistically significant depression in baseline (prethymosin) counts from both normals and patients when individuals whose counts increased in the presence of thymosin were compared with other subjects. The authors conclude that thymosin tended to raise depressed blastogenesis into the normal range without causing supranormal activity or without itself acting as a mitogen or antigen. Eighty two in vivo courses of thymosin were given to 32 patients. Analysis of the first thymosin courses in these 32 patients shows that immunologic reconstitution occurred in patients with originally depressed T cell function and numbers, whereas little change was apparent in patients with initially intact tests of T cell activity. Clinical effects were equivocal; however, no systematic clinical trial was conducted. Toxicity was minimal (four of the 32 patients); in each case, it consisted of inflammation at the injection site. The in vitro and in vivo results of this study suggest that thymosin therapy modulates and partially normalizes T lymphocyte numbers and function.

Original languageEnglish (US)
Pages (from-to)609-620
Number of pages12
JournalAnnals of the New York Academy of Sciences
VolumeVol. 277
StatePublished - 1976
Externally publishedYes

Fingerprint

Thymosin
T-cells
Neoplasms
T-Lymphocytes
Lymphocytes
Mitogens
Cell culture
Toxicity
In Vitro Techniques
Cancer Patients
Lymphocyte Count
Lymphocyte Activation
Antigens
Reference Values
Cell Culture Techniques
Cell Count
Clinical Trials
Inflammation
Injections

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Schafer, L. A., Goldstein, A. L., Gutterman, J. U., & Hersh, E. M. (1976). In vitro and in vivo studies with thymosin in cancer patients. Annals of the New York Academy of Sciences, Vol. 277, 609-620.

In vitro and in vivo studies with thymosin in cancer patients. / Schafer, L. A.; Goldstein, A. L.; Gutterman, J. U.; Hersh, Evan M.

In: Annals of the New York Academy of Sciences, Vol. Vol. 277, 1976, p. 609-620.

Research output: Contribution to journalArticle

Schafer, LA, Goldstein, AL, Gutterman, JU & Hersh, EM 1976, 'In vitro and in vivo studies with thymosin in cancer patients', Annals of the New York Academy of Sciences, vol. Vol. 277, pp. 609-620.
Schafer, L. A. ; Goldstein, A. L. ; Gutterman, J. U. ; Hersh, Evan M. / In vitro and in vivo studies with thymosin in cancer patients. In: Annals of the New York Academy of Sciences. 1976 ; Vol. Vol. 277. pp. 609-620.
@article{c7e073b1202a4a51a75b4e05fbf54327,
title = "In vitro and in vivo studies with thymosin in cancer patients",
abstract = "Thymosin, fraction V, prepared by the method of Goldstein et al., was studied in in vitro lymphocyte cultures with cells obtained from normal subjects and patients with disseminated cancer. Thymosin lowered blastogenic activity in some patients, did not affect it in others, and increased counts in still others. There was a statistically significant depression in baseline (prethymosin) counts from both normals and patients when individuals whose counts increased in the presence of thymosin were compared with other subjects. The authors conclude that thymosin tended to raise depressed blastogenesis into the normal range without causing supranormal activity or without itself acting as a mitogen or antigen. Eighty two in vivo courses of thymosin were given to 32 patients. Analysis of the first thymosin courses in these 32 patients shows that immunologic reconstitution occurred in patients with originally depressed T cell function and numbers, whereas little change was apparent in patients with initially intact tests of T cell activity. Clinical effects were equivocal; however, no systematic clinical trial was conducted. Toxicity was minimal (four of the 32 patients); in each case, it consisted of inflammation at the injection site. The in vitro and in vivo results of this study suggest that thymosin therapy modulates and partially normalizes T lymphocyte numbers and function.",
author = "Schafer, {L. A.} and Goldstein, {A. L.} and Gutterman, {J. U.} and Hersh, {Evan M}",
year = "1976",
language = "English (US)",
volume = "Vol. 277",
pages = "609--620",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - In vitro and in vivo studies with thymosin in cancer patients

AU - Schafer, L. A.

AU - Goldstein, A. L.

AU - Gutterman, J. U.

AU - Hersh, Evan M

PY - 1976

Y1 - 1976

N2 - Thymosin, fraction V, prepared by the method of Goldstein et al., was studied in in vitro lymphocyte cultures with cells obtained from normal subjects and patients with disseminated cancer. Thymosin lowered blastogenic activity in some patients, did not affect it in others, and increased counts in still others. There was a statistically significant depression in baseline (prethymosin) counts from both normals and patients when individuals whose counts increased in the presence of thymosin were compared with other subjects. The authors conclude that thymosin tended to raise depressed blastogenesis into the normal range without causing supranormal activity or without itself acting as a mitogen or antigen. Eighty two in vivo courses of thymosin were given to 32 patients. Analysis of the first thymosin courses in these 32 patients shows that immunologic reconstitution occurred in patients with originally depressed T cell function and numbers, whereas little change was apparent in patients with initially intact tests of T cell activity. Clinical effects were equivocal; however, no systematic clinical trial was conducted. Toxicity was minimal (four of the 32 patients); in each case, it consisted of inflammation at the injection site. The in vitro and in vivo results of this study suggest that thymosin therapy modulates and partially normalizes T lymphocyte numbers and function.

AB - Thymosin, fraction V, prepared by the method of Goldstein et al., was studied in in vitro lymphocyte cultures with cells obtained from normal subjects and patients with disseminated cancer. Thymosin lowered blastogenic activity in some patients, did not affect it in others, and increased counts in still others. There was a statistically significant depression in baseline (prethymosin) counts from both normals and patients when individuals whose counts increased in the presence of thymosin were compared with other subjects. The authors conclude that thymosin tended to raise depressed blastogenesis into the normal range without causing supranormal activity or without itself acting as a mitogen or antigen. Eighty two in vivo courses of thymosin were given to 32 patients. Analysis of the first thymosin courses in these 32 patients shows that immunologic reconstitution occurred in patients with originally depressed T cell function and numbers, whereas little change was apparent in patients with initially intact tests of T cell activity. Clinical effects were equivocal; however, no systematic clinical trial was conducted. Toxicity was minimal (four of the 32 patients); in each case, it consisted of inflammation at the injection site. The in vitro and in vivo results of this study suggest that thymosin therapy modulates and partially normalizes T lymphocyte numbers and function.

UR - http://www.scopus.com/inward/record.url?scp=0017103459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017103459&partnerID=8YFLogxK

M3 - Article

C2 - 136916

AN - SCOPUS:0017103459

VL - Vol. 277

SP - 609

EP - 620

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -